recruitment

1st RRMS Patient Enrolled in ENSURE-2 Trial of Oral IMU-838

The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeuticsā€™ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…

#ECTRIMS2016 – GeNeuro Reaches Enrollment Halfway Mark in Study of GNbAC1 to Treat Multiple Sclerosis

GeNeuroĀ announced that it has reached ā€” more quickly than expected ā€” the halfway mark for patient enrollment inĀ itsĀ Phase 2b study, CHANGE-MS,Ā assessingĀ GNbAC1 as a therapy forĀ relapsing-remitting multiple sclerosis (RRMS). Patient recruitmentĀ is continuing at sites across Europe. The company alsoĀ reported onĀ theĀ trial’s design in a poster presentation, “A placebo…